<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763566</url>
  </required_header>
  <id_info>
    <org_study_id>15530</org_study_id>
    <secondary_id>I3Y-CR-JPBQ</secondary_id>
    <nct_id>NCT02763566</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer</brief_title>
  <acronym>MONARCH plus</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in
      postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor
      receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 5, 2016</start_date>
  <completion_date type="Anticipated">November 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) (Abemaciclib + NSAI &amp; Placebo NSAI)</measure>
    <time_frame>Randomization to Measured Progressive Disease or Death (up to 26 Months)</time_frame>
    <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)</measure>
    <time_frame>Randomization to Measured Progressive Disease or Death (up to 26 Months)</time_frame>
    <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to Date of Death from Any Cause (Estimated up to 38 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]</measure>
    <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
    <description>Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 38 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]</measure>
    <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
    <description>Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]</measure>
    <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
    <description>Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions &amp; no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline through 19 Months</time_frame>
    <description>consists of 30 items covered by 1 of 3 dimensions:
Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent).
Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much)
Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much).
Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 &amp; M20)</measure>
    <time_frame>C1D1 post dose, C2D1 post dose, C3D1 predose, C4D1 predose</time_frame>
    <description>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) &amp; LSN3106726 (M20) was reported.
C=Cycle, D=day;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + NSAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Fulvestrant</arm_group_label>
    <arm_group_label>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</arm_group_label>
    <arm_group_label>Placebo + NSAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</arm_group_label>
    <arm_group_label>Placebo + NSAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo + Fulvestrant</arm_group_label>
    <arm_group_label>Placebo + NSAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Administered intramuscularly</description>
    <arm_group_label>Abemaciclib + Fulvestrant</arm_group_label>
    <arm_group_label>Placebo + Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of HR+, HER2- breast cancer. Although not required as a protocol
             procedure, metastatic disease should be considered for biopsy whenever possible to
             reassess hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)
             status if clinically indicated.

               -  To fulfill the requirement for HR+ disease, a breast cancer must express, by
                  immunohistochemistry (IHC), at least 1 of the HRs (estrogen receptor [ER],
                  progesterone receptor [PgR]) as defined in the relevant American Society of
                  Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

               -  To fulfill the requirement of HER2- disease, a breast cancer must not
                  demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of
                  HER2 by either IHC or in-situ hybridization as defined in the relevant ASCO/CAP
                  guidelines.

          -  Meet either Inclusion Criterion (2a) or Inclusion Criterion (2b). Participants meeting
             Inclusion Criterion 2a will be enrolled in Cohort A and participants meeting Inclusion
             Criterion 2b will be enrolled in Cohort B.

          -  (2a) Have locoregionally recurrent disease not amenable to resection or radiation
             therapy with curative intent or metastatic disease.

               -  Relapsed with radiologic evidence of progression more than 1 year from completion
                  of adjuvant endocrine therapy and have received no prior endocrine therapy for
                  locoregionally recurrent or metastatic disease (Note: prior adjuvant endocrine
                  therapy for localized disease may have included, but is not limited to,
                  anti-estrogens or aromatase inhibitors. In addition, a participant may be
                  enrolled if she has received ≤2 weeks of NSAI in this disease setting immediately
                  preceding screening and agrees to discontinue NSAI until study treatment
                  initiation.) OR

               -  Presented de novo metastatic breast cancer (mBC) and not received any prior
                  endocrine therapy.

          -  (2b) Have locoregionally recurrent disease not amenable to resection or radiation
             therapy with curative intent or metastatic disease.

               -  Relapsed with radiologic evidence of progression while receiving neoadjuvant or
                  adjuvant endocrine therapy, with no subsequent endocrine therapy received
                  following progression OR

               -  Relapsed with radiologic evidence of progression within 1 year from completion of
                  adjuvant endocrine therapy, with no subsequent endocrine therapy received
                  following progression OR

               -  Relapsed with radiologic evidence of progression more than 1 year from completion
                  of adjuvant endocrine therapy and then subsequently relapsed with radiologic
                  evidence of progression after receiving treatment with either an antiestrogen or
                  an aromatase inhibitor as firstline endocrine therapy for metastatic disease.
                  Participants may not have received more than 1 line of endocrine therapy or any
                  prior chemotherapy for metastatic disease OR

               -  Presented de novo with metastatic disease and then relapsed with radiologic
                  evidence of progression after receiving treatment with either an antiestrogen or
                  an aromatase inhibitor as first-line endocrine therapy for metastatic disease.
                  Participants may not have received more than 1 line of endocrine therapy or any
                  prior chemotherapy for metastatic disease.

          -  Have postmenopausal status defined as meeting at least 1 of the following:

               -  Prior bilateral oophorectomy

               -  Age ≥60 years

               -  Age &lt;60 years and amenorrheic for at least 12 months (in the absence of
                  chemotherapy, tamoxifen, toremifene, or ovarian suppression) and
                  follicle-stimulating hormone (FSH) and estradiol levels in the postmenopausal
                  range.

          -  Have 1 of the following, as defined by the Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1:

               -  Measurable disease

               -  Nonmeasurable bone-only disease. Nonmeasurable bone-only disease may include any
                  of the following: blastic bone lesions, lytic bone lesions without a measurable
                  soft tissue component, or mixed lytic-blastic bone lesions without a measurable
                  soft tissue component.

          -  Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology (ECOG) scale.

          -  Have adequate organ function, including:

               -  Hematologic: absolute neutrophil count (ANC) ≥1.5 × 109/Liter (L), platelets

                  ≥100 × 109/L, and hemoglobin ≥8 g/deciliter (dL). Participants may receive
                  erythrocyte transfusions to achieve this hemoglobin level at the discretion of
                  the investigator; however, initial study drug treatment must not begin earlier
                  than the day after the erythrocyte transfusion.

               -  Hepatic: Total bilirubin ≤1.5 times the upper limit of normal (ULN) and alanine
                  aminotransferase (ALT) and aspartate aminotransferase (AST)

                  ≤3.0 times ULN (or ALT and AST ≤5 times ULN if liver metastases are present).

               -  Renal: serum creatinine ≤1.5 times ULN.

          -  Have discontinued previous localized radiotherapy for palliative purposes or for lytic
             lesions at risk of fracture at least 2 weeks prior to randomization and recovered from
             the acute effects of therapy (until the toxicity resolves to either baseline or at
             least Grade 1) except for residual alopecia or peripheral neuropathy.

          -  Are able to swallow capsules.

          -  Are reliable, willing to be available for the duration of the study, and willing to
             follow study procedures.

        Exclusion Criteria:

          -  Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis. Visceral
             crisis is not the mere presence of visceral metastases, but implies severe organ
             dysfunction as assessed by symptoms and signs, laboratory studies, and rapid
             progression of the disease.

          -  Have inflammatory breast cancer.

          -  Have clinical evidence or a history of central nervous system (CNS) metastasis.
             Screening test is not required for enrollment.

          -  Are currently receiving or have previously received chemotherapy for locoregionally
             recurrent or metastatic breast cancer. (Note: Participants may be enrolled if they
             received prior [neo]adjuvant chemotherapy for localized disease.)

          -  Have received prior treatment with everolimus or fulvestrant (for Cohort B only).

          -  Have received prior treatment with any cyclin-dependent kinases 4 and 6 (CDK4 and
             CDK6) inhibitor (or participated in any CDK4 and CDK6 inhibitor clinical trial for
             which treatment assignment is still blinded).

          -  Have initiated bisphosphonates or approved Receptor activator of nuclear factor
             kappa-B ligand (RANK-L) targeted agents &lt;7 days prior to randomization.

          -  Are currently enrolled in a clinical trial involving an investigational product (IP)
             or non-approved use of a drug or device (other than the IP/device used in this study),
             or concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study. If a participant is currently
             enrolled in a clinical trial involving non-approved use of a device, then agreement
             with the investigator and Eli Lilly and Company (Lilly) clinical research physician
             (CRP) is required to establish eligibility.

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of randomization for a nonmyelosuppressive or
             myelosuppressive agent, respectively.

          -  Have had major surgery within 14 days prior to randomization to allow for
             post-operative healing of the surgical wound and site(s).

          -  Have received recent (within 28 days prior to randomization) live attenuated vaccines
             such as yellow fever vaccine.

          -  Have serious preexisting medical conditions that, in the judgment of the investigator,
             would preclude participation in this study (eg, history of major surgical resection
             involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative
             colitis).

          -  Have a personal history within the last 12 months of any of the following conditions:
             syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation,
             or sudden cardiac arrest.

          -  Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma
             in-situ of the cervix), unless in complete remission with no therapy for a minimum of
             3 years.

          -  Have received an autologous or allogeneic stem-cell transplant.

          -  Have clinical evidence of active bacterial or fungal infection or active viral
             infection that, in the judgment of the investigator, would preclude participation in
             this study (eg, human immunodeficiency virus [HIV] or viral hepatitis). Screening test
             is not required for enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Caridade Ijui</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Câncer - Hospital Mãe de Deus Center/AESC</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação PIO XII</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784700</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base Fac de Medicina de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose Rio Preto</city>
        <state>Sao Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo - ICESP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária</name>
      <address>
        <city>São Paulo</city>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afflilated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 307th Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Province Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Guangxi Medical University</name>
      <address>
        <city>Nan Ning</city>
        <state>Guang XI</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Province People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Caner Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Tongji Hospital</name>
      <address>
        <city>Wuhan City</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union (Xiehe) Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hu Bei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Province Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province Tumor Hospital</name>
      <address>
        <city>Chang Chun</city>
        <state>Ji Lin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian Med. Univ. No 2 Affiliate Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liao Ning</state>
        <zip>116023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Cander Hospital&amp;Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>100042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical Universit</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Medical College, Xi'an Jiaotong</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hang Zhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliate Hospital of Zhejiang Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tumor Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Tumor Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. B. L. Kapur Memorial Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gujarat Cancer &amp; Research Institute (GCRI)</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Global Enterprises Limited (HCG)</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560095</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College and Hospital</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Superspecialty Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Oncology Centre of Rosebank</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastleigh Breast Care Center</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>India</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/breast-cancer/JPBQ#?postal=</url>
    <description>Click here for more information about this study: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer</description>
  </link>
  <verification_date>February 17, 2020</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <results_first_submitted>March 16, 2020</results_first_submitted>
  <results_first_submitted_qc>March 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone Receptor-Positive</keyword>
  <keyword>HER2-Negative</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02763566/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02763566/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who died due to any cause or disease progression or alive and on study at conclusion but off treatment are considered as completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
          <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + NSAI</title>
          <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Abemaciclib + Fulvestrant</title>
          <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Fulvestrant</title>
          <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On study treatment at study conclusion</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
          <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + NSAI</title>
          <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Abemaciclib + Fulvestrant</title>
          <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Fulvestrant</title>
          <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="10.8"/>
                    <measurement group_id="B2" value="55.5" spread="9.8"/>
                    <measurement group_id="B3" value="59.7" spread="8.5"/>
                    <measurement group_id="B4" value="58.2" spread="10.3"/>
                    <measurement group_id="B5" value="57.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="413"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) (Abemaciclib + NSAI &amp; Placebo NSAI)</title>
        <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
        <time_frame>Randomization to Measured Progressive Disease or Death (up to 26 Months)</time_frame>
        <population>All randomized participants in Abemaciclib + NSAI &amp; Placebo NSAI arms. Censored participants: 141 in Abemaciclib + NSAI, 46 in Placebo + NSAI.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + NSAI</title>
            <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) (Abemaciclib + NSAI &amp; Placebo NSAI)</title>
          <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
          <population>All randomized participants in Abemaciclib + NSAI &amp; Placebo NSAI arms. Censored participants: 141 in Abemaciclib + NSAI, 46 in Placebo + NSAI.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="22.32" upper_limit="NA">Median and Upper bound were not estimable due to Immature data.</measurement>
                    <measurement group_id="O2" value="14.73" lower_limit="11.21" upper_limit="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.346</ci_lower_limit>
            <ci_upper_limit>0.719</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)</title>
        <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
        <time_frame>Randomization to Measured Progressive Disease or Death (up to 26 Months)</time_frame>
        <population>All randomized participants in Abemaciclib + Fulvestrant and Placebo + Fulvestrant arms.
Censored participants: 58 in Abemaciclib + Fulvestrant, 17 in Placebo + Fulvestrant.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Fulvestrant</title>
            <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)</title>
          <description>Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.</description>
          <population>All randomized participants in Abemaciclib + Fulvestrant and Placebo + Fulvestrant arms.
Censored participants: 58 in Abemaciclib + Fulvestrant, 17 in Placebo + Fulvestrant.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.47" lower_limit="9.53" upper_limit="NA">Upper bound was not estimable due to Immature data.</measurement>
                    <measurement group_id="O2" value="5.59" lower_limit="3.65" upper_limit="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.376</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.240</ci_lower_limit>
            <ci_upper_limit>0.588</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>Randomization to Date of Death from Any Cause (Estimated up to 38 Months)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]</title>
        <description>Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.</description>
        <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + NSAI</title>
            <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Fulvestrant</title>
            <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]</title>
          <description>Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="49.3" upper_limit="62.8"/>
                    <measurement group_id="O2" value="30.3" lower_limit="21.3" upper_limit="39.4"/>
                    <measurement group_id="O3" value="38.5" lower_limit="29.1" upper_limit="47.8"/>
                    <measurement group_id="O4" value="7.5" lower_limit="0.4" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 38 Months)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]</title>
        <description>Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
        <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + NSAI</title>
            <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Fulvestrant</title>
            <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]</title>
          <description>Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="87.5" upper_limit="95.1"/>
                    <measurement group_id="O2" value="82.8" lower_limit="75.4" upper_limit="90.3"/>
                    <measurement group_id="O3" value="92.3" lower_limit="87.2" upper_limit="97.4"/>
                    <measurement group_id="O4" value="69.8" lower_limit="57.5" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0456</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]</title>
        <description>Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions &amp; no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
        <time_frame>Randomization to Measured Progressive Disease (up to 26 Months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + NSAI</title>
            <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Fulvestrant</title>
            <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]</title>
          <description>Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions &amp; no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="77.4" upper_limit="87.8"/>
                    <measurement group_id="O2" value="62.6" lower_limit="53.1" upper_limit="72.2"/>
                    <measurement group_id="O3" value="77.9" lower_limit="69.9" upper_limit="85.9"/>
                    <measurement group_id="O4" value="45.3" lower_limit="31.9" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)</title>
        <description>consists of 30 items covered by 1 of 3 dimensions:
Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent).
Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much)
Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much).
Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.</description>
        <time_frame>Baseline through 19 Months</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline EORTC-QLQ-C30 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + NSAI</title>
            <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.</description>
          </group>
          <group group_id="O3">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Fulvestrant</title>
            <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)</title>
          <description>consists of 30 items covered by 1 of 3 dimensions:
Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent).
Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much)
Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much).
Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline EORTC-QLQ-C30 measurement.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Health Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.99"/>
                    <measurement group_id="O2" value="4.26" spread="1.47"/>
                    <measurement group_id="O3" value="-0.35" spread="1.41"/>
                    <measurement group_id="O4" value="3.12" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scales - Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.82"/>
                    <measurement group_id="O2" value="-0.01" spread="1.21"/>
                    <measurement group_id="O3" value="-1.11" spread="1.06"/>
                    <measurement group_id="O4" value="-2.70" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scales - Role Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.20"/>
                    <measurement group_id="O2" value="-1.38" spread="1.79"/>
                    <measurement group_id="O3" value="-3.76" spread="1.35"/>
                    <measurement group_id="O4" value="-2.04" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scales - Emotional Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.98"/>
                    <measurement group_id="O2" value="-0.10" spread="1.44"/>
                    <measurement group_id="O3" value="0.43" spread="1.27"/>
                    <measurement group_id="O4" value="0.18" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scales - Cognitive Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.90"/>
                    <measurement group_id="O2" value="-0.72" spread="1.35"/>
                    <measurement group_id="O3" value="-3.52" spread="1.35"/>
                    <measurement group_id="O4" value="-1.10" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Scales - Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="1.19"/>
                    <measurement group_id="O2" value="-1.57" spread="1.75"/>
                    <measurement group_id="O3" value="-2.03" spread="1.71"/>
                    <measurement group_id="O4" value="-2.67" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.95"/>
                    <measurement group_id="O2" value="0.06" spread="1.40"/>
                    <measurement group_id="O3" value="4.19" spread="1.44"/>
                    <measurement group_id="O4" value="1.46" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Nausea and Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.60"/>
                    <measurement group_id="O2" value="-0.33" spread="0.88"/>
                    <measurement group_id="O3" value="4.26" spread="1.10"/>
                    <measurement group_id="O4" value="1.67" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.44" spread="0.91"/>
                    <measurement group_id="O2" value="-4.90" spread="1.35"/>
                    <measurement group_id="O3" value="-2.82" spread="1.36"/>
                    <measurement group_id="O4" value="-0.17" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="1.02"/>
                    <measurement group_id="O2" value="0.35" spread="1.53"/>
                    <measurement group_id="O3" value="-1.66" spread="1.27"/>
                    <measurement group_id="O4" value="0.83" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="1.07"/>
                    <measurement group_id="O2" value="-0.05" spread="1.60"/>
                    <measurement group_id="O3" value="1.53" spread="1.59"/>
                    <measurement group_id="O4" value="-0.44" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="0.97"/>
                    <measurement group_id="O2" value="-1.47" spread="1.44"/>
                    <measurement group_id="O3" value="8.67" spread="1.63"/>
                    <measurement group_id="O4" value="1.21" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="0.98"/>
                    <measurement group_id="O2" value="-1.49" spread="1.46"/>
                    <measurement group_id="O3" value="-1.63" spread="1.31"/>
                    <measurement group_id="O4" value="0.65" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.72" spread="0.85"/>
                    <measurement group_id="O2" value="-0.10" spread="1.27"/>
                    <measurement group_id="O3" value="16.03" spread="1.26"/>
                    <measurement group_id="O4" value="-1.80" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Scales - Financial Difficulties</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" spread="1.65"/>
                    <measurement group_id="O2" value="-1.27" spread="2.46"/>
                    <measurement group_id="O3" value="-6.36" spread="1.76"/>
                    <measurement group_id="O4" value="-9.35" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global Health Status</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.287</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.36</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Physical functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Role Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.55</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Emotional Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.340</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>5.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Cognitive Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.37</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.678</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.355</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>4.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Nausea and Vomiting</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.372</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.740</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Dyspnoea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.240</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>2.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom scales - Insomnia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.673</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.60</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Appetite</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>5.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>9.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Constipation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.04</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Diarrhoea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>15.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.81</ci_lower_limit>
            <ci_upper_limit>18.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Financial Difficulties</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.59</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Global Health Status</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-3.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.43</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Physical Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.400</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Role functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.472</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.42</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Emotional Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.310</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.12</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Social Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.830</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.26</ci_lower_limit>
            <ci_upper_limit>6.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>2.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.26</ci_lower_limit>
            <ci_upper_limit>7.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Nausea and Vomiting</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>2.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>6.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.45</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Dyspnoea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.280</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.04</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Insomnia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.499</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>1.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.78</ci_lower_limit>
            <ci_upper_limit>7.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Appetite</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>7.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>13.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Constipation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.83</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Diarrhoea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>17.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.25</ci_lower_limit>
            <ci_upper_limit>22.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Symptom Scales - Financial DIfficulties</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>2.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>9.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Scales - Cognitive functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.12</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 &amp; M20)</title>
        <description>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) &amp; LSN3106726 (M20) was reported.
C=Cycle, D=day;</description>
        <time_frame>C1D1 post dose, C2D1 post dose, C3D1 predose, C4D1 predose</time_frame>
        <population>All randomized participants who received at least one dose of Abemaciclib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
            <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Abemaciclib + Fulvestrant</title>
            <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 &amp; M20)</title>
          <description>Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) &amp; LSN3106726 (M20) was reported.
C=Cycle, D=day;</description>
          <population>All randomized participants who received at least one dose of Abemaciclib and had evaluable PK data.</population>
          <units>Nanogram*hour per Millilitre (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abemaciclib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2720" spread="40"/>
                    <measurement group_id="O2" value="2740" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSN2839567 (M2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1080" spread="84"/>
                    <measurement group_id="O2" value="861" spread="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSN3106726 (M20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1970" spread="81"/>
                    <measurement group_id="O2" value="1570" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 Months</time_frame>
      <desc>All randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)</title>
          <description>Participants received Abemaciclib orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + NSAI</title>
          <description>Participants received Placebo orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Abemaciclib + Fulvestrant</title>
          <description>Participants received Abemaciclib orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
        <group group_id="E4">
          <title>Placebo + Fulvestrant</title>
          <description>Participants received Placebo orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urostomy complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Iiird nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="462" subjects_affected="127" subjects_at_risk="205"/>
                <counts group_id="E2" events="39" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E3" events="206" subjects_affected="73" subjects_at_risk="104"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="101" subjects_affected="36" subjects_at_risk="205"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" events="32" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="12" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="960" subjects_affected="164" subjects_at_risk="205"/>
                <counts group_id="E2" events="45" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E3" events="449" subjects_affected="82" subjects_at_risk="104"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="75" subjects_affected="54" subjects_at_risk="205"/>
                <counts group_id="E2" events="30" subjects_affected="19" subjects_at_risk="99"/>
                <counts group_id="E3" events="25" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E4" events="17" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="18" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="205"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" events="29" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="87" subjects_affected="60" subjects_at_risk="205"/>
                <counts group_id="E2" events="41" subjects_affected="25" subjects_at_risk="99"/>
                <counts group_id="E3" events="35" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="42" subjects_affected="30" subjects_at_risk="205"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="38" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" events="15" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="205"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="99"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="143" subjects_affected="71" subjects_at_risk="205"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="99"/>
                <counts group_id="E3" events="68" subjects_affected="36" subjects_at_risk="104"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="142" subjects_affected="71" subjects_at_risk="205"/>
                <counts group_id="E2" events="35" subjects_affected="21" subjects_at_risk="99"/>
                <counts group_id="E3" events="53" subjects_affected="32" subjects_at_risk="104"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="52" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="38" subjects_affected="22" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="91" subjects_affected="34" subjects_at_risk="205"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="56" subjects_affected="22" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="17" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="953" subjects_affected="164" subjects_at_risk="205"/>
                <counts group_id="E2" events="44" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E3" events="392" subjects_affected="84" subjects_at_risk="104"/>
                <counts group_id="E4" events="29" subjects_affected="10" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="247" subjects_affected="90" subjects_at_risk="205"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="100" subjects_affected="43" subjects_at_risk="104"/>
                <counts group_id="E4" events="13" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="64" subjects_affected="38" subjects_at_risk="205"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="891" subjects_affected="156" subjects_at_risk="205"/>
                <counts group_id="E2" events="58" subjects_affected="27" subjects_at_risk="99"/>
                <counts group_id="E3" events="374" subjects_affected="86" subjects_at_risk="104"/>
                <counts group_id="E4" events="24" subjects_affected="12" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="70" subjects_affected="48" subjects_at_risk="205"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" events="34" subjects_affected="23" subjects_at_risk="104"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="25" subjects_at_risk="205"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="18" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="205"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E2" events="23" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="25" subjects_at_risk="205"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="205"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="36" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

